Search research articles
Contact Us
Filters
Showing results (31-40 of 41) with videos related to
Page
of 5
Sort By:
International Journal of Hematology
|
December 16, 2011
Epstein-Barr virus-associated post-transplant lymphoproliferative disorders after allogeneic peripheral blood stem cell transplantation for Hodgkin-like adult T-cell leukemia/lymphoma
Toshinari Yagi, Jun Ishikawa, Nana Aono, et al.
Oncology
|
May 11, 2023
The Glasgow Prognostic Score Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Who Are Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
Yuki Akazawa, Satoshi Igawa, Kaori Yamada, et al.
Lung Cancer (Amsterdam, Netherlands)
|
July 2, 2025
Phase III study of ramucirumab plus docetaxel versus atezolizumab for previously treated PD-L1 low or negative advanced non-small-cell lung cancer: WJOG10317L study
Yoshitaka Zenke, Seiji Niho, Yukihiro Toi, et al.
Oncology
|
September 14, 2022
The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung Cancer
Masashi Kasajima, Satoshi Igawa, Hiroya Manaka, et al.
Lung Cancer (Amsterdam, Netherlands)
|
July 2, 2025
Durvalumab plus irinotecan + cisplatin for untreated extensive-stage small cell lung cancer: REBORN, phase II study (WJOG13520L)
Motoko Tachihara, Hiroyasu Shoda, Yuki Akazawa, et al.
Cancer Treatment and Research Communications
|
January 16, 2026
Differential predictive value of baseline tumor size according to PD-L1 expression in advanced NSCLC treated with immune checkpoint inhibitors
Hiroki Ito, Masayuki Shirasawa, Yuki Akazawa, et al.
Biochemical and Biophysical Research Communications
|
February 11, 2023
Iroquois homeobox 3 regulates odontoblast proliferation and differentiation mediated by Wnt5a expression
Anrizandy Narwidina, Aya Miyazaki, Kokoro Iwata, et al.
Journal for Immunotherapy of Cancer
|
February 19, 2020
Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L)
Ryoji Kato, Hidetoshi Hayashi, Yasutaka Chiba, et al.
International Journal of Clinical Oncology
|
October 13, 2021
Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B)
Yukari Tsubata, Kana Watanabe, Ryota Saito, et al.
International Journal of Clinical Oncology
|
March 8, 2022
Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B)
Yukari Tsubata, Kana Watanabe, Ryota Saito, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 41) with videos related to
Sort By:
Page
of 5
International Journal of Hematology
|
December 16, 2011
Epstein-Barr virus-associated post-transplant lymphoproliferative disorders after allogeneic peripheral blood stem cell transplantation for Hodgkin-like adult T-cell leukemia/lymphoma
Toshinari Yagi, Jun Ishikawa, Nana Aono, et al.
Oncology
|
May 11, 2023
The Glasgow Prognostic Score Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Who Are Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
Yuki Akazawa, Satoshi Igawa, Kaori Yamada, et al.
Lung Cancer (Amsterdam, Netherlands)
|
July 2, 2025
Phase III study of ramucirumab plus docetaxel versus atezolizumab for previously treated PD-L1 low or negative advanced non-small-cell lung cancer: WJOG10317L study
Yoshitaka Zenke, Seiji Niho, Yukihiro Toi, et al.
Oncology
|
September 14, 2022
The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung Cancer
Masashi Kasajima, Satoshi Igawa, Hiroya Manaka, et al.
Lung Cancer (Amsterdam, Netherlands)
|
July 2, 2025
Durvalumab plus irinotecan + cisplatin for untreated extensive-stage small cell lung cancer: REBORN, phase II study (WJOG13520L)
Motoko Tachihara, Hiroyasu Shoda, Yuki Akazawa, et al.
Cancer Treatment and Research Communications
|
January 16, 2026
Differential predictive value of baseline tumor size according to PD-L1 expression in advanced NSCLC treated with immune checkpoint inhibitors
Hiroki Ito, Masayuki Shirasawa, Yuki Akazawa, et al.
Biochemical and Biophysical Research Communications
|
February 11, 2023
Iroquois homeobox 3 regulates odontoblast proliferation and differentiation mediated by Wnt5a expression
Anrizandy Narwidina, Aya Miyazaki, Kokoro Iwata, et al.
Journal for Immunotherapy of Cancer
|
February 19, 2020
Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L)
Ryoji Kato, Hidetoshi Hayashi, Yasutaka Chiba, et al.
International Journal of Clinical Oncology
|
October 13, 2021
Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B)
Yukari Tsubata, Kana Watanabe, Ryota Saito, et al.
International Journal of Clinical Oncology
|
March 8, 2022
Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B)
Yukari Tsubata, Kana Watanabe, Ryota Saito, et al.
Page
of 5